Is there still a role for talimogene laherparepvec (T-VEC) in advanced melanoma? An indirect efficacy comparison of T-VEC plus ipilimumab combination therapy versus T-VEC alone as salvage therapy in unresectable metastatic melanoma-Reference-Cited by-同舟云学术

Is there still a role for talimogene laherparepvec (T-VEC) in advanced melanoma? An indirect efficacy comparison of T-VEC plus ipilimumab combination therapy versus T-VEC alone as salvage therapy in unresectable metastatic melanoma

Published:2021-10-31 Issue:12 Volume:21 Page:1647-1653
ISSN:1471-2598
Container-title:Expert Opinion on Biological Therapy
language:en
Short-container-title:Expert Opinion on Biological Therapy

Author:

Fazel Mohammad¹,AlRawashdh Neda²³,Alamer Ahmad³⁴^ORCID,Curiel-Lewandrowski Clara¹,Abraham Ivo²³⁵⁶^ORCID

Affiliation:

1. Division of Dermatology, College of Medicine, University of Arizona, Tucson, AZ, USA

2. Department of Clinical Translational Sciences, College of Medicine, University of Arizona, Tucson, AZ, USA

3. Center for Health Outcomes and PharmacoEconomic Research, University of Arizona, Tucson, AZ, USA

4. Department of Clinical Pharmacy, College of Pharmacy, Prince Sattam Bin Abdulaziz University, Alkharj, Saudi Arabia

5. Department of Pharmacy Practice and Science, College of Pharmacy, University of Arizona, Tucson, AZ, USA

6. University of Arizona Cancer Center, University of Arizona, Tucson, AZ, USA

Funder

not funded

Publisher

Informa UK Limited

Subject

Clinical Biochemistry,Drug Discovery,Pharmacology

Link

https://www.tandfonline.com/doi/pdf/10.1080/14712598.2022.1998450

Reference28 articles.

1. Final analyses of OPTiM: a randomized phase III trial of talimogene laherparepvec versus granulocyte-macrophage colony-stimulating factor in unresectable stage III–IV melanoma

2. Talimogene Laherparepvec combined with anti-PD-1 based immunotherapy for unresectable stage III-IV melanoma: a case series

3. Talimogene laherparepvec: review of its mechanism of action and clinical efficacy and safety

4. Talimogene laherparepvec treatment to overcome loco-regional acquired resistance to immune checkpoint blockade in tumor stage IIIB–IV M1c melanoma patients

5. Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Clitoral metastasis of vulvar melanoma treated with talimogene laherparepvec;JAAD Case Reports;2023-02